Frontiers in Pharmacology (Feb 2024)
Emerging role of antidiabetic drugs in cardiorenal protection
- Wen-Jia Fu,
- Wen-Jia Fu,
- Wen-Jia Fu,
- Wen-Jia Fu,
- Jin-Ling Huo,
- Jin-Ling Huo,
- Jin-Ling Huo,
- Jin-Ling Huo,
- Zi-Hui Mao,
- Zi-Hui Mao,
- Zi-Hui Mao,
- Zi-Hui Mao,
- Shao-Kang Pan,
- Shao-Kang Pan,
- Shao-Kang Pan,
- Shao-Kang Pan,
- Dong-Wei Liu,
- Dong-Wei Liu,
- Dong-Wei Liu,
- Dong-Wei Liu,
- Zhang-Suo Liu,
- Zhang-Suo Liu,
- Zhang-Suo Liu,
- Zhang-Suo Liu,
- Peng Wu,
- Peng Wu,
- Peng Wu,
- Peng Wu,
- Zhong-Xiuzi Gao,
- Zhong-Xiuzi Gao,
- Zhong-Xiuzi Gao,
- Zhong-Xiuzi Gao
Affiliations
- Wen-Jia Fu
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Wen-Jia Fu
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Wen-Jia Fu
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Wen-Jia Fu
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Jin-Ling Huo
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Jin-Ling Huo
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Jin-Ling Huo
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Jin-Ling Huo
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Zi-Hui Mao
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Zi-Hui Mao
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Zi-Hui Mao
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Zi-Hui Mao
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Shao-Kang Pan
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Shao-Kang Pan
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Shao-Kang Pan
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Shao-Kang Pan
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Dong-Wei Liu
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Dong-Wei Liu
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Dong-Wei Liu
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Dong-Wei Liu
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Zhang-Suo Liu
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Zhang-Suo Liu
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Zhang-Suo Liu
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Zhang-Suo Liu
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Peng Wu
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Peng Wu
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Peng Wu
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Peng Wu
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- Zhong-Xiuzi Gao
- Traditional Chinese Medicine Integrated Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- Zhong-Xiuzi Gao
- Institute of Nephrology, Zhengzhou University, Zhengzhou, China
- Zhong-Xiuzi Gao
- Henan Province Research Center for Kidney Disease, Zhengzhou, China
- Zhong-Xiuzi Gao
- Key Laboratory of Precision Diagnosis and Treatment for Chronic Kidney Disease in Henan Province, Zhengzhou, China
- DOI
- https://doi.org/10.3389/fphar.2024.1349069
- Journal volume & issue
-
Vol. 15
Abstract
The global prevalence of diabetes mellitus (DM) has led to widespread multi-system damage, especially in cardiovascular and renal functions, heightening morbidity and mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dipeptidyl peptidase-4 inhibitors (DPP-4i) have demonstrated efficacy in preserving cardiac and renal function, both in type 2 diabetic and non-diabetic individuals. To understand the exact impact of these drugs on cardiorenal protection and underlying mechanisms, we conducted a comprehensive review of recent large-scale clinical trials and basic research focusing on SGLT2i, GLP-1RAs, and DPP-4i. Accumulating evidence highlights the diverse mechanisms including glucose-dependent and independent pathways, and revealing their potential cardiorenal protection in diabetic and non-diabetic cardiorenal disease. This review provides critical insights into the cardiorenal protective effects of SGLT2i, GLP-1RAs, and DPP-4i and underscores the importance of these medications in mitigating the progression of cardiovascular and renal complications, and their broader clinical implications beyond glycemic management.
Keywords
